Sovaprevir

Sovaprevir
Clinical data

ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name (4R)-N-{(1R,2S)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-1-{(2S)-3,3-dimethyl-2-[2-oxo-2-(1-piperidinyl)ethyl]butanoyl}-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolinamide
Synonyms	ACH-1625
CAS Number	1001667-23-7
PubChem CID	53362096
ChemSpider	28529313
UNII	2ND9V3MN6O
KEGG	D10166
ChEMBL	CHEMBL2105750
NIAID ChemDB	491583
Chemical and physical data
Formula	C₄₃H₅₃N₅O₈S
Molar mass	799.98 g/mol
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7
InChI InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1 Key:MHFMTUBUVQZIRE-WINRQGAFSA-N

Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.^[1]

Sovaprevir received Fast Track status from the U.S. Food and Drug Administration (FDA) in 2012.^[2]

References

↑ De Clercq, E (15 June 2014). "Current Race in the Development of DAAs (Direct-Acting Antivirals) Against HCV". Biochemical Pharmacology. 89 (4): 441–52. PMID 24735613. doi:10.1016/j.bcp.2014.04.005.
↑ Sovaprevir HCV NS3/4A Protease Inhibitor

External links

Achillion Provides Pipeline Update

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Ciluprevir^§ Danoprevir^† Faldaprevir^‡ Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir^# Sovaprevir^† Telaprevir Vaniprevir Vedroprevir^§ Voxilaprevir
NS5A inhibitors (–asvir)	Daclatasvir^# Elbasvir Ledipasvir Odalasvir^† Ombitasvir Pibrentasvir Ravidasvir^† Ruzasvir^† Samatasvir^† Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Dasabuvir^# Deleobuvir^§ Filibuvir^§ Setrobuvir^§ Sofosbuvir^# Radalbuvir^† Uprifosbuvir^†
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir^# Ombitasvir/paritaprevir/ritonavir^# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir/voxilaprevir Velpatasvir/sofosbuvir

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

Umifenovir

neuraminidase inhibitors/release phase (Oseltamivir^#
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^#
Multiple/unknown	BCX4430^† Favipiravir GS-5734^† Mericitabine^† MK-608^§ NITD008^§ Moroxydine Ribavirin^#/Taribavirin^† Triazavirin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.